Healthcare / Health Information ServicesASX
$0.08
+0.00 (+1.20%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-443063.00 · quality 69.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
37/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2M
P/E
8.4x
↓EV/EBITDA
N/A
•ROE
-14.3%
↓Gross Margin
50.1%
↑Debt/Equity
0.22
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+65.0%
FCF CAGR
—
FCF margin
-17.7%
FCF / Net income
3.07x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.2M · net income $-128795.0 · FCF $-395681.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.2M | $2.2M | $814732.00 | $1.1M | $496858.00 |
| Net Income | $-128795.00 | $-128795.00 | $-761248.00 | $-116112.00 | $-531030.00 |
| EBITDA | $-85256.00 | $-85256.00 | $-612842.00 | $-53922.00 | $-471249.00 |
| EPS | -0.00 | -0.00 | -0.04 | -0.01 | -0.03 |
| Gross Margin | 50.1% | 50.1% | 59.1% | 63.7% | 70.3% |
| Operating Margin | -29.2% | -29.2% | -123.6% | -55.2% | -165.7% |
| Net Margin | -5.8% | -5.8% | -93.4% | -10.6% | -106.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.22 | 0.22 | 0.29 | 0.23 | 0.21 |
| Current Ratio | 1.95 | 1.95 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-395681.00 | $-395681.00 | $-547357.00 | $-443063.00 | $-632934.00 |
| Returns | |||||
| ROE | -14.3% | -14.3% | -73.8% | -9.4% | -39.5% |
| Valuation | |||||
| P/E | 8.40 | 8.40 | — | — | — |
| P/B | 2.51 | 2.51 | 1.20 | 1.33 | 1.01 |
| Growth & Yield | |||||
| Revenue Growth | 173.7% | 173.7% | -25.8% | 120.9% | — |
| EPS Growth | 88.9% | 88.9% | -533.8% | 78.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+16.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.04 → -0.00
Residual
+16.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.